Company Analysis

Gossamer Bio, Inc. (GOSS)

Nasdaq: GOSS · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2018
Grade4.0
◀ Past 3.2● Present 4.6▶ Future 4.0
2 est.

Who runs Gossamer Bio, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Hasnain Faheem
President & CEO. First filing Feb 2019, latest Aug 26, 2026, 7 filings in all.
Officers reporting now
6
of 13 people with a filing in the last fifteen months
Directors reporting now
7
21 people on the record since 2019
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Hasnain FaheemPresident & CEOFeb 2019Aug 26, 2026none
Giraudo BryanCOO/CFOFeb 2019Aug 26, 2026none
Peterson CarynChief Development OfficerApr 2021Aug 26, 2026none
Smith Robert Paul JrChief Commercial OfficerDec 2023Aug 26, 2026none
Christian WaageEVP, Tech Ops and AdminFeb 2019Aug 26, 2026none
Aranda RichardChief Medical OfficerJun 2021Mar 20, 2026none
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Ciongoli Gregory AustindirectorSep 2026Sep 25, 2026none
Cox Russell J.directorFeb 2019Sep 25, 2026none
Daniel Thomas OdirectorFeb 2019Sep 25, 2026none
Drynan SkyedirectorMar 2024Sep 25, 2026none
Milligan SandradirectorJun 2021Sep 25, 2026none
Nathan Steven DdirectorMar 2024Sep 25, 2026none
Quisel John DdirectorNov 2023Sep 25, 2026none
Earlier names on the record19, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton GOSS · research, not advice